GutSee Health develops precision microbiome therapies that re‑engineer the gut ecosystem to treat chronic disorders such as IBS and IBD. Their proprietary AI discovery platform integrates multi‑omics data to identify therapeutic targets, enabling a dual‑pronged approach that adds beneficial bacteria and removes harmful strains with targeted phages. This AI‑driven, phage‑biotic treatment aims to provide lasting, disease‑modifying restoration of gut health.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic gut disorders such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) affect millions of people worldwide, yet current treatments are largely symptomatic and fail to provide lasting relief for a large proportion of patients.
Solution
GutSee Health creates precision microbiome therapies that actively re‑engineer the gut ecosystem to address the underlying causes of IBS and IBD. The company’s proprietary AI discovery platform integrates multi‑omics data to map microbial interactions, metabolic disruptions, and disease‑driving pathways. Using a dual‑pronged phage‑biotic approach, the therapy adds beneficial bacterial strains while selectively removing harmful microbes with targeted bacteriophages. This targeted modulation aims to restore a balanced microbiome, delivering durable, disease‑modifying outcomes. The platform also supports patient stratification and pharmacokinetic insights, enabling more precise clinical trial design and drug development.
Target Audience
Primary customers are pharmaceutical companies and biotech firms developing gut‑focused therapeutics, as well as clinical research organizations conducting IBS and IBD trials.
Features
- AI‑driven multi‑omics analysis that identifies key microbial signatures and metabolic pathways linked to gut disorders
- Dual‑action phage‑biotic formulation that simultaneously introduces therapeutic bacteria and eliminates pathogenic strains
- Targeted bacteriophage technology providing strain‑specific microbial depletion without broad‑spectrum antibiotic effects
- Scalable manufacturing process designed for consistent dosing and reproducible microbiome modulation
- Integrated biomarker pipeline for patient selection and monitoring of therapeutic response
- Compatibility with clinical trial workflows to accelerate pharmacokinetic and efficacy assessments